Abstract In this review, we discuss the anabolic and metabolic responses of skeletal muscles to β2-agonists and exercise. β2-agonists increase muscle mass, particularly in fast-twitch muscles. Exercise positively regulates glucose homeostasis, mitochondrial biogenesis, and metabolic enzyme levels in skeletal muscles; whereas treatment with β2-agonists attenuates these beneficial effects. This review also describes the role of β2-adrenergic receptor (β2-AR) signaling molecules, such as cyclic adenosine monophosphate response element-binding protein, mitogen-activated protein kinase, and Akt/protein kinase B, in the response of skeletal muscles to β2-agonist treatment and exercise. For example, β2-agonists and exercise increase the phosphorylation of p38 mitogen-activated protein kinase in slow-twitch muscles. Our interpretation of these findings is that β2-adrenergic receptor signaling plays a functional role in the anabolic and metabolic responses of skeletal muscles to β2-agonists and exercise.
Introduction
Skeletal muscles can adapt to a range of different physiological challenges. For example, resistance training increases muscle mass, fiber hypertrophy, and strength 1) . In contrast, endurance training results in increased mitochondrial density, capillary density, changes in key metabolic enzyme levels, and increased maximal oxygen uptake 2, 3) . These adaptations of skeletal muscles to exercise are mediated, at least in part, by β2-adrenergic receptors (β2-ARs) 4) . The β2-AR, a member of the guanine nucleotide-binding G protein-coupled receptor (GPCR) family, has 7 transmembrane α helices forming 3 extracellular loops, including an NH2 terminus and 3 intracellular loops that include a COOH terminus 5) . Skeletal muscles contain a significant proportion of β-ARs, of which the β2 subtype is the most abundant, while approximately 7-10% of β-ARs are of the β1 subtype 6) . Furthermore, β2-AR is more expressed in slow-twitch fibers than in fast-twitch fibers 7) and is often a pharmacological target for performance-enhancing drugs in sports.
In modern sports, many types of doping drugs have been used by athletes to improve athletic performance despite many negative reactions and side effects 8, 9) . β2-agonists, such as clenbuterol, salbutamol, and fenoterol ( Fig. 1 ), increase muscle mass and power 8, 9) . According to the recent reports by the World Anti-Doping Agency, the β2-agonist clenbuterol was the seventh most commonly used anabolic agent in 2009 (67 cases; 2.0% of all anabolic agents used).
The role of β2-AR signaling in the regulation of protein metabolism in skeletal muscles remains to be elucidated. Understanding the mechanism of adaptation of skeletal muscles to β2-AR activation could lead to the eradication of its use in sports doping. Thus, in this review, we dis-*Present address: Department of Molecular Predictive Medicine and Sport Science, Kyorin University, School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo 181-8611, Japan **Correspondence: imaizumi@waseda.jp cuss the effects of β2-agonists and exercise on the β2-AR signaling pathway in skeletal muscles.
Anabolic and metabolic adaptations to β2-agonists and exercise
Numerous studies have shown that β2-agonists induce muscle hypertrophy in many species [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . Experiments in mice lacking β1-AR, β2-AR, or both subtypes, have demonstrated that clenbuterol-induced effects, such as muscle hypertrophy, are mediated by β2-AR 10) . β2-agonists promote muscle growth by stimulating protein synthesis and reducing protein degradation [11] [12] [13] . Furthermore, the hypertrophic response to β2-agonists is known to appear more frequently in fast-twitch muscles [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . In addition to hypertrophic action, clenbuterol also induces the transformation of slow-twitch muscles to fast-twitch muscles [myosin heavy chain (MHC)I/β → MHCIIa → MHCIId/ x → MHCIIb] 14) . However, the mechanisms by which β2-agonists exert fiber type-dependent effects on muscle hypertrophy remain unclear.
In general, physical activity elicits physiological responses in skeletal muscles and in turn results in numerous health benefits. In the acute state, exercise positively regulates glucose homeostasis by enhancing glucose transport and insulin action in skeletal muscles 2, 23) . Chronic physical activity increases glucose transporter 4 protein levels and mitochondrial enzyme expression, and modulates the fiber type in skeletal muscles 2, 24, 25) . However, supplementing strength training with clenbuterol treatment has no synergistic benefit on the development of muscle mass or metabolic enzyme levels 26) . In addition to strength training, β2-agonists also offset the beneficial effects of endurance training, such as contractile activity 27) , muscle fiber type shift 27) , metabolic enzyme activity 28) , and insulin resistance 29) . Thus, β2-agonists counteract the beneficial effects of the physiological response to exercise in skeletal muscles.
Effects of β2-agonists and exercise on the Gαs-adenylyl cyclase (AC)-cyclic adenosine monophosphate (cAMP) pathway in skeletal muscles
It is known that β2-AR can couple to the Gαs and Gαi signaling pathways (Fig. 2) . Gαs-AC-cAMP pathway activation stimulates phosphorylation of the C subunit of protein kinase A (PKA), as illustrated in Fig. 2 . Phosphorylated PKA regulates the activity of several proteins, including cAMP response element (CRE)-binding protein (CREB) 11, 13) . However, single-dose clenbuterol treatment and acute exercise do not affect the level of CREB phosphorylation in skeletal muscles (Table 1) 22) , suggesting that the response of skeletal muscles to β2-agonists and exercise is not primarily dependent upon the activation of CREB. From these findings, it may be concluded that the Gαs-AC-cAMP pathway is not activated by β2-agonistsor exercise-induced β2-AR stimulation.
Effects of β2-agonists and exercise on mitogen-activated protein kinase (MAPK) pathway in skeletal muscles
In addition to its well-documented inhibition of AC activity, β2-AR coupling to Gαi appears to activate Gαs-independent pathways (Fig. 2) . In one such pathway, the receptor-coupled Gαi dissociates from the heterodimeric Gβγ complex, and free Gβγ subunits then activate the MAPK signaling pathway 11, 13, 30) . The MAPK family, including the extracellular signalregulated kinase 1/2 (ERK1/2), c-Jun N-terminal kinase/ stress-activated protein kinase, and p38 MAPK, is a ubiquitous group of signaling proteins involved in the control of cell growth, differentiation, and adaptation. In skeletal muscles, p38 MAPK activation is necessary for myogenic cell differentiation 31, 32) and is involved in the regulation of glucose metabolism and energy expenditure 33, 34) . Some studies have shown that β2-agonists and exercise influence the phosphorylation of p38 MAPK in skeletal muscles (Table 1) . Recently, our group has demonstrated that p38 MAPK phosphorylation is increased, with an occasional increase in p38γ subunit phosphorylation, in slowtwitch muscles after single-dose clenbuterol treatment and acute exercise 22) . However, this effect was not witnessed in fast-twitch muscles 22) . In addition, it has been shown that skeletal muscle contraction, stretch, and overload increases the phosphorylation of p38 MAPK, with an occasional increase in phosphorylated p38γ subunits 35) , to a greater extent in slow-twitch muscles than in fast-twitch muscles 35, 36) . It has been demonstrated that the p38γ subunit is a key regulator in skeletal muscle metabolic adaptation 37) and Fig. 1 Chemical structure of adrenaline and common synthetic β 2 -agonists. metabolism, mitochondrial biogenesis, and muscle fiber type specialization 40) , activation of p38 MAPK by β2-agonists and exercise may be responsible, at least in part, for oxidative and aerobic adaptations, particularly in slow-twitch muscles.
On the contrary, clenbuterol increases the phosphorylation and activity of ERK1/2 to a greater extent in fasttwitch muscles than in slow-twitch muscles (Table 1) 19) . Furthermore, it has been demonstrated that ablation of ERK1/2 inhibits the effect of clenbuterol treatment on fast-twitch fiber-specific gene expression, while having little effect on slow-twitch fiber-specific genes 19) . These is required for the maintenance of slow-twitch skeletal muscle size, while having no such effects on fast-twitch muscles 38) . These findings suggest that β2-agonist-and exercise-induced activation of p38γ MAPK are involved in the anabolic adaptation of slow-twitch muscles. Furthermore, Miura et al. 4) have shown that an exercise-induced increase in peroxisome proliferator-activated receptor γ coactivatior 1α (PGC-1α) mRNA is mediated by β2-AR activation. In a more detailed investigation, it was shown that exercise stimulates PGC-1α transcription in skeletal muscle via activation of the p38 MAPK pathway 39) . Given that PGC-1α regulates adaptive thermogenesis, glucose findings suggest that activation of ERK1/2 is necessary for the β2-agonist-induced hypertrophic process in fasttwitch muscles.
Effects of β2-agonists and exercise on phosphoinositol 3-kinase (PI3K)-Akt/protein kinase B (PKB) pathway in skeletal muscles
Free Gβγ subunits activate the PI3K-Akt signaling pathway (Fig. 2) 11, 13, 41) , which has also been implicated in protein synthesis, gene transcription, cell proliferation, and cell survival 42) . As shown in Table 1 , studies in rats have shown that single-dose clenbuterol treatment increases the phosphorylation of Akt in fast-twitch muscles, but not slow-twitch muscles 43, 44) . In contrast to rat models, singledose administration of clenbuterol in mice increased the phosphorylation of Akt in slow-twitch muscles 44) . Recently, our group found that Akt phosphorylation in slowtwitch muscles is increased by single-dose clenbuterol treatment in mice, while the fast-twitch muscles were unaffected 22) . These findings indicate that the effect of β2-agonists on the phosphorylation of Akt differs between fiber types and species. Moreover, pharmacological inhibition of the Akt signaling pathway revealed that the anabolic response to clenbuterol treatment in rats is greater in fast-twitch muscles than in slow-twitch muscles 43) . Therefore, activation of Akt in skeletal muscles in response to β2-AR stimulation may account for the anabolic adaptation. Table 1 also shows the effects of exercise, overloading, stretch, and electrical stimulation on the phosphorylation and activity of Akt in skeletal muscles. We have recently found that there is no change in the phosphorylation of Akt after acute exercise in skeletal muscles 22) . Some studies have shown that exercise increases the phosphorylation and activity of Akt in rat skeletal muscles 45, 46) , whereas others have observed no such effect 47) . Passive stretch and electrical stimulation of rat skeletal muscles was also found to increase the phosphorylation and activity of Akt in fast-twitch muscles, but not in slow-twitch muscles [46] [47] [48] . These findings indicate that the phosphorylation level of Akt differs between experimental models in relation to the intensity of exercise, load, and contraction. However, further experiments are needed to confirm this observation.
Effects of β2-agonists and exercise on a current target of β2-AR signaling, the orphan nuclear receptor, NOR-1, in skeletal muscles
The NOR-1, known in rats as NR4A3, is thought to be involved in the regulation of genes that control glucose and fatty acid utilization in skeletal muscles. Recently, Pearen et al. 49) identified that the promoter region of NOR-1 is a target for β2-AR-mediated CRE activation in skeletal muscles. An increase in the expression of NOR-1, induced by β2-AR activation, is consistent with the involvement of PKA, p38 MAPK, and phosphorylated CREB in C2C12 cells 50) . Additionally, NOR-1 was found to be a negative regulator of myostatin (a member of the transforming growth factor-β superfamily and a potent negative regulator of muscle mass) 49) . Furthermore, Kawasaki et al. 51) demonstrated that acute exercise increases the expression of NOR-1 mRNA in skeletal muscles. These results suggest that β2-AR activation, through increased NOR-1 expression, inhibits myostatin expression, and thus induces muscle hypertrophy.
Conclusion
This review has discussed the effects of β2-agonists and exercise on β2-AR signaling in skeletal muscles, which reveals the similarity and difference in the response of β2-AR signaling molecules between β2-agonists and exercise. These findings highlight that β2-AR signaling plays a functional role in anabolic and metabolic adaptations to β2-agonists and exercise in skeletal muscles. The insights mentioned in this review will provide scientific evidence for the eradication of β2-agonists as sports doping agents in terms of furthering our knowledge of the mechanisms of muscle hypertrophy.
